Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2014 Oct 19;41(6):675–691. doi: 10.1007/s10928-014-9393-x

Table A.1.

The PK study dosing regimens and observation schedules for AMG925, sorafenib and AC220. In BID studies, the two doses each day were 6 hours apart. The doses were chosen from in vitro and PK analysis to ensure in vivo plasma level coverage of in vitro EC50 by either QD or BID dosing regimens.

Compound Dosing Regimen Observation Times (hours) Number of Animals
AMG925 BID 37.5 mg/Kg for 1 day 3, 9, 12, 24 3
BID 25 mg/Kg for 1 day 3, 9, 12, 24 3
BID 12.5 mg/Kg for 1 day 3, 9, 12, 24 3
BID 37.5 mg/Kg for 10 days 240, 241, 243, 248, 252, 264 3
BID 25 mg/Kg for 10 days 240, 241, 243, 248, 252, 264 3
BID 12.5 mg/Kg for 10 days 240, 241, 243, 248, 252, 264 3
BID 6.25 mg/Kg for 10 days 240, 241, 243, 248, 252, 264 3
QD 150 mg/Kg for 8 days 216, 217, 219, 222, 240 2
Sorafenib QD 10 mg/Kg for 1 day 3, 6, 24 2
QD 3 mg/Kg for 1 day 3, 6, 24 2
QD 1 mg/Kg for 1 day 3, 6, 24 2
AC220 QD 3 mg/Kg for 1 day 3, 8, 14, 24 3
QD 1 mg/Kg for 1 day 3, 8, 14, 24 3
QD 0.5 mg/Kg for 1 day 3, 8, 14, 24 3
QD 0.1 mg/Kg for 1 day 3, 8, 14, 24 3